HeartBeam Appoints Bryan Humbarger as Chief Commercial Officer to Drive Cardiac Technology Commercialization

HeartBeam announced the appointment of Bryan Humbarger as chief commercial officer, effective January 22, 2026. In this newly created role, Humbarger will lead commercial strategy and execution across key growth initiatives for the medical technology company. His responsibilities include overseeing the limited launch of the recently cleared HeartBeam System for arrhythmia assessment and heart attack detection indication, along with a 12-lead ECG extended wear patch monitor. The appointment comes as HeartBeam expands outreach to cardiology partners to validate real-world performance and establish reference sites for broader adoption of its cardiac monitoring technology.

The company's technology represents a significant advancement in cardiac care, creating the first-ever cable-free device capable of collecting ECG signals in three dimensions from three non-coplanar directions and synthesizing these signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever patients are located, delivering actionable heart intelligence to physicians. The technology enables healthcare providers to identify cardiac health trends and acute conditions while directing patients to appropriate care outside traditional medical facilities, potentially redefining cardiac health management.

HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, with the 12-Lead ECG synthesis software receiving clearance in December 2025. The company's cleared indications for use, available at https://www.heartbeam.com/indications, detail the intended applications of this innovative technology. The system's ability to provide comprehensive cardiac monitoring outside clinical settings addresses a critical need in healthcare, particularly for patients requiring ongoing cardiac assessment who may not have regular access to medical facilities.

The appointment of Humbarger as chief commercial officer signals HeartBeam's transition from technology development to market implementation. His leadership will be crucial in establishing the clinical and commercial infrastructure necessary for widespread adoption of the HeartBeam System. As the company moves forward with its commercialization strategy, investors and industry observers can follow developments through the company's newsroom at https://ibn.fm/BEAT. The success of this commercialization effort could significantly impact how cardiac conditions are detected and monitored, potentially improving outcomes for patients with heart disease through earlier intervention and more continuous monitoring capabilities.